{"doi":"10.1136/esmoopen-2020-001079","title":"Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial","abstract":"PURPOSE: To report updated analyses of the phase III CheckMate 214 trial with extended minimum follow-up assessing long-term outcomes with first-line nivolumab plus ipilimumab (NIVO+IPI) versus (vs) sunitinib (SUN) in patients with advanced renal cell carcinoma (aRCC). METHODS: Patients with aRCC with a clear cell component were stratified by International Metastatic Renal Cell Carcinoma Database Consortium risk and randomised to NIVO (3 mg/kg) plus IPI (1 mg/kg) every three weeks ×4 doses, followed by NIVO (3 mg/kg) every two weeks; or SUN (50 mg) once per day ×4 weeks (6-week cycle). Efficacy endpoints included overall survival (OS), progression-free survival (PFS) and objective response rate (ORR) per independent radiology review committee in patients with intermediate/poor-risk disease (I/P; primary), intent-to-treat patients (ITT; secondary) and in patients with favourable-risk disease (FAV; exploratory). RESULTS: Overall, 1096 patients were randomised (ITT: NIVO+IPI, n=550, SUN, n=546; I/P: NIVO+IPI, n=425, SUN, n=422; FAV: NIVO+IPI, n=125, SUN, n=124). After 4 years minimum follow-up, OS (HR; 95% CI) remained superior with NIVO+IPI vs SUN in ITT (0.69; 0.59 to 0.81) and I/P patients (0.65; 0.54 to 0.78). Four-year PFS probabilities were 31.0% vs 17.3% (ITT) and 32.7% vs 12.3% (I/P), with NIVO+IPI vs SUN. ORR remained higher with NIVO+IPI vs SUN in ITT (39.1% vs 32.4%) and I/P (41.9% vs 26.8%) patients. In FAV patients, the HRs (95% CI) for OS and PFS were 0.93 (0.62 to 1.40) and 1.84 (1.29 to 2.62); ORR was lower with NIVO+IPI vs SUN. However, more patients in all risk groups achieved complete responses with NIVO+IPI: ITT (10.7% vs 2.6%), I/P (10.4% vs 1.4%) and FAV (12.0% vs 6.5%). Probability (95% CI) of response ≥4 years was higher with NIVO+IPI vs SUN (ITT, 59% (0.51 to 0.66) vs 30% (0.21 to 0.39); I/P, 59% (0.50 to 0.67) vs 24% (0.14 to 0.36); and FAV, 60% (0.41 to 0.75) vs 38% (0.22 to 0.54)) regardless of risk category. Safety remained favourable with NIVO+IPI vs SUN. CONCLUSION: After long-term follow-up, NIVO+IPI continues to demonstrate durable efficacy benefits vs SUN, with manageable safety. TRIAL REGISTRATION DETAILS: ClinicalTrials.gov identifier: NCT02231749.","journal":"ESMO Open","year":2020,"id":48175,"datarank":6.449933163445722,"base_score":6.263398262591624,"endowment":6.263398262591624,"self_citation_contribution":0.9395097393887437,"citation_network_contribution":5.510423424056979,"self_endowment_contribution":0.9395097393887437,"citer_contribution":5.510423424056979,"corpus_percentile":null,"corpus_rank":null,"citation_count":524,"citer_count":100,"citers_with_citation_signal":100,"citers_with_endowment":100,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9153,"is_data_producer":true,"deposit_databanks":{"ClinicalTrials.gov":["NCT02231749"]},"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2020-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":226674,"name":"Nizar M. Tannir","orcid":"0000-0001-5559-8060","position":1,"is_corresponding":false},{"id":226675,"name":"Mauricio Burotto","orcid":"0000-0002-7150-4033","position":2,"is_corresponding":false},{"id":95252,"name":"David F. McDermott","orcid":"0000-0002-2675-5095","position":3,"is_corresponding":false},{"id":226676,"name":"Elizabeth R. Plimack","orcid":"0000-0002-7618-0744","position":4,"is_corresponding":false},{"id":226677,"name":"Philippe Barthélémy","orcid":"0000-0003-3917-0579","position":5,"is_corresponding":false},{"id":226678,"name":"Camillo Porta","orcid":"0000-0003-2412-1563","position":6,"is_corresponding":false},{"id":229488,"name":"Thomas Powles","orcid":null,"position":7,"is_corresponding":false},{"id":226679,"name":"Frede Donskov","orcid":"0000-0002-8449-863X","position":8,"is_corresponding":false},{"id":226680,"name":"Saby George","orcid":"0000-0002-0444-5870","position":9,"is_corresponding":false},{"id":226681,"name":"Christian Kollmannsberger","orcid":"0000-0002-6329-761X","position":10,"is_corresponding":false},{"id":226682,"name":"Howard Gurney","orcid":"0000-0003-0217-5261","position":11,"is_corresponding":false},{"id":226683,"name":"Marc‐Oliver Grimm","orcid":"0000-0003-3084-8654","position":12,"is_corresponding":false},{"id":226684,"name":"Yoshihiko Tomita","orcid":"0000-0002-7465-9591","position":13,"is_corresponding":false},{"id":105144,"name":"Daniel Castellano","orcid":"0000-0002-9106-0687","position":14,"is_corresponding":false},{"id":105189,"name":"Brian I. Rini","orcid":"0000-0002-2212-080X","position":15,"is_corresponding":false},{"id":16405,"name":"Toni K. Choueiri","orcid":"0000-0002-9201-3217","position":16,"is_corresponding":false},{"id":229489,"name":"Shruti Shally Saggi","orcid":null,"position":17,"is_corresponding":false},{"id":226685,"name":"M. Brent McHenry","orcid":"0000-0001-9159-3304","position":18,"is_corresponding":false},{"id":226686,"name":"Robert J. Motzer","orcid":"0000-0001-6925-2327","position":19,"is_corresponding":false},{"id":91592,"name":"Laurence Albigès","orcid":"0000-0002-5734-3480","position":0,"is_corresponding":true}],"reference_count":15,"raw_metadata":null,"created_at":"2026-07-18T20:34:12.647743Z","pmid":"33246931","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}